Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence

• In spite of its proven heuristic value, the dopamine hypothesis of schizophrenia is now yielding to a multifactorial view, in which the other monoamines as well as glutamate and GABA are included, with a focus on neurotransmitter interactions in complex neurocircuits. The primary lesion(s) in schizophrenia does not necessarily involve any of these neurotransmitters directly but could deal with a more general defect, such as a faulty connectivity of developmental origin. Nevertheless, a precise identification of neurotransmitter aberrations in schizophrenia will probably provide clues for a better understanding of the disease and for the development of new treatment and prevention strategies.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

Animals

Antipsychotic Agents/pharmacology/therapeutic use

Biogenic Monoamines/*physiology

Brain Chemistry/physiology

Dopamine/physiology

Glutamic Acid/*physiology

Humans

Schizophrenia/drug therapy/metabolism/*physiopathology

gamma-Aminobutyric Acid/*physiology

Publikations- och innehållstyp

ref (ämneskategori)

for (ämneskategori)